High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.021
-14.91%
--
--
-1.090
+14.74%
--
--
-1.125
-0.44%
Estimates Revision
The market is revising No Change the revenue expectations for Apogee Therapeutics, Inc. (APGE) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 99.37%.
EPS Estimates for FY2025
Revise Downward
-6.07%
In Past 3 Month
Stock Price
Go Up
+99.37%
In Past 3 Month
8 Analyst Rating
Wall Street analysts forecast APGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APGE is 95.00 USD with a low forecast of 70.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 75.500
Low
70.00
Averages
95.00
High
115.00
Current: 75.500
Low
70.00
Averages
95.00
High
115.00
Craig-Hallum
NULL -> Buy
initiated
$109
2025-11-03
Reason
Craig-Hallum
Price Target
$109
2025-11-03
initiated
NULL -> Buy
Reason
Craig-Hallum initiated coverage of Apogee Therapeutics with a Buy rating and $109 price target.
Craig-Hallum
NULL -> Buy
initiated
$109
2025-11-03
Reason
Craig-Hallum
Price Target
$109
2025-11-03
initiated
NULL -> Buy
Reason
As previously reported, Craig-Hallum initiated coverage of Apogee Therapeutics with a Buy rating and $109 price target. The firm notes Apogee is a clean, well-capitalized immunology platform building Dupixent 2.0 with its long-acting IL-13 antibody APG777, initially targeting the $20B+ atopic dermatitis market. 52-week durability data in Q1 2026 and a high-exposure induction cohort in Q2 2026 could show best-in-class efficacy and convenience, setting up a path to front-line use and expansion into asthma, COPD, and EoE, the firm says.
RBC Capital
Brian Abrahams
Outperform
maintain
$60 -> $70
2025-11-03
Reason
RBC Capital
Brian Abrahams
Price Target
$60 -> $70
2025-11-03
maintain
Outperform
Reason
RBC Capital analyst Brian Abrahams raised the firm's price target on Apogee Therapeutics to $70 from $60 and keeps an Outperform rating on the shares. Following the firm's opportunity to catch up with Apogee's senior management on the latest updates to their clinical programs and developments in the AD - atopic dermatitis - space, RBC notes that its discussion has reaffirmed its confidence that the upcoming AD readouts should look favorable, the analyst tells investors in a research note. With timeline acceleration and the space continuing to grow, Apogee's '777 and future combos can be poised to drive meaningful revenue opportunity, the firm added.
Mizuho
Joseph Catanzaro
Outperform
initiated
$105
2025-10-20
Reason
Mizuho
Joseph Catanzaro
Price Target
$105
2025-10-20
initiated
Outperform
Reason
Mizuho analyst Joseph Catanzaro initiated coverage of Apogee Therapeutics with an Outperform rating and $105 price target. The firm believes the company's APG777 is positioned to play a "significant role" in Th2 inflammatory diseases, namely atopic dermatitis. Phase II readouts in 2026 should validate the drug's once-quarterly maintenance dosing and "best-in-class" biologic efficacy, the analyst tells investors in a research note.
RBC Capital
Outperform
initiated
$60
2025-09-25
Reason
RBC Capital
Price Target
$60
2025-09-25
initiated
Outperform
Reason
RBC Capital initiated coverage of Apogee Therapeutics with an Outperform rating and $60 price target. The firm is optimistic on the company's potential to deliver clinically differentiated biologics. Apogee's early clinical and more recent Phase II atopic dermatitis data demonstrated APG777 and its combo therapies' advantageous properties, the analyst tells investors in a research note. RBC sees large revenue opportunities across several immunology and inflammation indications.
BTIG
NULL -> Buy
maintain
$100 -> $115
2025-07-11
Reason
BTIG
Price Target
$100 -> $115
2025-07-11
maintain
NULL -> Buy
Reason
BTIG raised the firm's price target on Apogee Therapeutics to $115 from $100 and keeps a Buy rating on the shares. The firm notes that the new EASI-75 watermark for Biologics in Atopic Dermatitis exceeded its expectations and supports a market-leading profile, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Apogee Therapeutics Inc (APGE.O) is -17.19, compared to its 5-year average forward P/E of -12.17. For a more detailed relative valuation and DCF analysis to assess Apogee Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-12.17
Current PE
-17.19
Overvalued PE
-7.79
Undervalued PE
-16.55
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-6.49
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-1.98
Undervalued EV/EBITDA
-11.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 956.72% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 2216.65% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 956.72% over the last month.
Sold
Bought
APGE News & Events
Events Timeline
(ET)
2025-11-10
07:28:21
Apogee Therapeutics reveals preliminary Phase 1 findings for APG333
2025-11-10
07:26:22
Apogee Therapeutics projects funding to last through the second half of 2028.
2025-11-10
07:25:53
Apogee Therapeutics Announces Q3 Net Loss of $65 Million Compared to $49 Million Last Year
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/74073736d45ddcd268d9a9ffa0f92f641fac725d6322039dd6d5a92904729beb.png)
Preview
6.0
11-03BenzingaRBC Capital Reaffirms Outperform Rating for Apogee Therapeutics and Increases Price Target to $70
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/f2233dd3af39ac56dea70a4b3ba601fa73abf26c73b4c80c069f67da513d8d0e.jpg)
Preview
4.0
10-22NASDAQ.COMMizuho Begins Coverage of Apogee Therapeutics (APGE) with a Positive Outlook
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/a344f7c1741ac8f2a17ac04affda673dadce0d282e442fa4efcb7e38b38f1233.png)
Preview
4.0
10-21BenzingaMizuho Begins Coverage of Apogee Therapeutics with Outperform Rating and Sets Price Target at $105
Sign Up For More News
People Also Watch
FAQ
What is Apogee Therapeutics Inc (APGE) stock price today?
What is Apogee Therapeutics Inc (APGE)'s business?
What is the price predicton of APGE Stock?
What is Apogee Therapeutics Inc (APGE)'s revenue for the last quarter?
What is Apogee Therapeutics Inc (APGE)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Apogee Therapeutics Inc (APGE)'s fundamentals?
How many employees does Apogee Therapeutics Inc (APGE). have?